15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Organogenesis Holdings Inc, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $3.00 to $8.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $5.50 sits 117% above the current $2.53. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.13 next quarter toward $-0.28 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Organogenesis Holdings Inc.
As of Jul, 2 of 3 firms rate ORGO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ORGO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.13
Range $-0.13 – $-0.12 · 2 analysts · -170% YoY
Next period, 2 analysts expect Organogenesis Holdings Inc to earn $-0.13 a share (range $-0.13 – $-0.12), versus $0.18 a year earlier. Full-year consensus is $-0.82, growing to $-0.28 the year after.
REVENUE · NEXT QUARTER
$80.9M
Range $80.2M – $81.6M · 2 analysts · -46% YoY
Revenue is expected to reach $80.9M (range $80.2M – $81.6M), -46.4% year-over-year. Full-year consensus is $282.9M, rising to $337.6M next year.
Top analysts covering Organogenesis Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ORGO.
#1
Ross Osborn
Cantor Fitzgerald · Rank #139
Buy
$9.00+255.3% to target
Overall win rate
34%
+ Follow
#2
RM
Ravi Misra
Truist Securities
Hold
$3.00+18.4% to target
Coverage
—
+ Follow
#3
Ryan Zimmerman
BTIG
Buy
$8.00+215.8% to target
Coverage
—
+ Follow
#4
PW
Patrick Wood
Morgan Stanley
Hold
$6.00+136.9% to target
Coverage
—
+ Follow
ORGO stock forecast FAQ
What is ORGO's average 12-month price target?+
The 2 analysts with a live target average $5.50 for Organogenesis Holdings Inc over the next 12 months, ranging from a $8.00 high to a $3.00 low.
Is ORGO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ORGO?+
The Street-high target is $8.00 (BTIG), and the Street-low is $3.00 (Truist Securities). The average of all 2 active targets is $5.50.
How many Wall Street analysts cover ORGO?+
3 analysts have an active rating on Organogenesis Holdings Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering ORGO?+
Among analysts who currently cover ORGO, Ross Osborn of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #139). Their current call is Buy with a $9.00 target.
What is Organogenesis Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $-0.13 per share (range $-0.13 – $-0.12) across 2 analysts. Full-year EPS is projected at $-0.82, rising to $-0.28 the following year.
How much revenue is Organogenesis Holdings Inc expected to report next quarter?+
Consensus revenue is $80.9M (range $80.2M – $81.6M). Full-year revenue is projected at $282.9M, growing to $337.6M next year.
Have analysts been upgrading or downgrading ORGO lately?+
As of Jul, 2 of 3 firms rate ORGO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ORGO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
